A notice for Participants in the Add-Aspirin Breast Cohort

We were recently informed by the ABC breast cancer trial (A011502) team of a decision to stop their trial. Their oversight committee advised them that their trial was unlikely to show that aspirin would be better than placebo in preventing cancer returning. They reported no increase in side effects in patients receiving aspirin compared with those receiving placebo. The ABC trial team have advised that detailed results will be available in the first half of 2022.

Whilst the ABC trial was designed to answer a similar question to the one we are asking in Add-Aspirin, there are some important differences between the two trials. One difference is how long after being treated for breast cancer participants could join the trial. Add-Aspirin requires entry to the trial a few weeks after curative treatment for breast cancer. In the ABC trial participants could enter the trial up to 10 years after being treated for breast cancer. The ABC trial also allowed participants to enter who had previously been taking aspirin, provided they did not take it in the 30 days before starting the trial. In Add-Aspirin we do not allow regular prior aspirin use.

We provided all of this information to the Add-Aspirin oversight committee. They have advised that the Add-Aspirin trial should continue without any change. They will decide if they need to review their advice when further results from the ABC trial are available.

If you are a participant on the Add-Aspirin trial and have questions or concerns about this, please discuss them with your study nurse or doctor. You should continue to take your Add-Aspirin tablets and attend your scheduled follow-up visits.

The Add-Aspirin team would like to thank you for your continued participation in the Add-Aspirin study.